Efficacy of inactivated SARS-CoV-2 vaccination in pediatric hematology/oncology patients: a real-world study

Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has been spreading globally since its initial outbreak in 2019.Substantial evidence has revealed that children who are receiving antitumor therapy or hematopoietic stem cell transplantation(HSCT)present higher rates of severe illness and mortality[1].It is important to identify infected children with hematology and oncology diseases who have the ten-dency to develop worse outcomes of coronal virus disease 2019(COVID-19)during the early stage of COVID-19.